ATAC-seq tells you which regions of DNA are “open” and accessible in a cell at a given moment, revealing where genes are being actively regulated. Because DNA in our cells is tightly wound around proteins called histones, only certain stretches are unwound and exposed at any time. Those open stretches are where the cell’s regulatory machinery can bind, turning genes on or off. ATAC-seq maps exactly where those stretches are, giving you a snapshot of a cell’s regulatory landscape.
How the Technique Works
ATAC-seq relies on an enzyme called Tn5 transposase that acts like a molecular probe. This enzyme can only access DNA that isn’t tightly packed around histones. When it finds an exposed stretch, it simultaneously cuts the DNA and attaches small tags (sequencing adapters) to the cut ends, a process called tagmentation. Those tagged fragments are then collected and sequenced. The result is a map showing everywhere the enzyme was able to reach, which corresponds to the open, active portions of the genome.
The beauty of this approach is its simplicity. Older methods for mapping open chromatin, like DNase-seq, required careful calibration to avoid over-digesting or under-digesting the DNA, along with separate steps to prepare the fragments for sequencing. ATAC-seq combines cutting and tagging into a single reaction, reducing hands-on time and the risk of losing material during preparation. It also works with far less starting material: a standard experiment needs roughly 50,000 cells, and the technique has been scaled down to work on single cells.
What the Data Reveals
The core output of an ATAC-seq experiment is a set of “peaks,” regions of the genome where sequencing reads pile up. Each peak marks a spot where chromatin was open and the enzyme could cut. These peaks typically fall into two categories: promoters (the stretches right next to where a gene starts being read) and distant regulatory elements like enhancers, insulators, or silencers that control gene activity from farther away.
When a gene has several strong peaks at its promoter and along its length, that gene is generally being actively expressed in the cell type you’re studying. Comparing peaks between two different cell types reveals which regulatory regions are uniquely open in each one. A peak present in a liver cell but absent in a brain cell, for instance, points to a regulatory element driving liver-specific gene activity. This kind of differential accessibility analysis is one of the most common uses of ATAC-seq data.
Transcription Factor Binding
ATAC-seq can also reveal where specific regulatory proteins called transcription factors are physically sitting on the DNA. Within a broad open region, a bound transcription factor blocks the Tn5 enzyme from cutting at that exact spot. This creates a small dip in the signal, a “footprint,” nestled inside a larger peak of accessibility. Computational tools analyze these footprints to identify which transcription factors are actively bound, and even estimate the timing and strength of their binding.
This is a powerful alternative to other protein-binding assays that require an antibody specific to each transcription factor you want to study. With ATAC-seq footprinting, you can scan for hundreds of transcription factors in a single experiment by matching the footprint sequences to known binding motifs.
Nucleosome Positioning
The sizes of the DNA fragments produced during ATAC-seq carry their own layer of information. Short fragments, typically under 100 base pairs, come from regions completely free of nucleosomes (the protein spools DNA wraps around). Fragments around 200 base pairs correspond to DNA that was wrapped around a single nucleosome, while fragments near 400 base pairs span two nucleosomes, and so on. When you plot all fragment sizes in a histogram, you see a characteristic pattern of peaks at roughly 200 base pair intervals, reflecting this nucleosome spacing.
Researchers use this pattern to map where nucleosomes sit along the genome, which matters because nucleosome positioning directly influences whether a transcription factor can access its target sequence. A well-positioned nucleosome sitting on top of a regulatory element effectively silences it.
Single-Cell Resolution
The single-cell version of this technique, scATAC-seq, applies the same logic to individual cells rather than a bulk population. This is important because a tissue sample contains many different cell types, each with its own pattern of open and closed chromatin. Bulk ATAC-seq averages all of those patterns together, potentially masking what’s happening in rare cell populations.
With scATAC-seq, each cell gets its own chromatin accessibility profile. Cells with similar profiles cluster together, allowing researchers to identify distinct cell types based purely on their regulatory landscape, without needing to know in advance what cell types are present. This has proven especially useful for dissecting complex tissues like tumors, developing organs, and the brain, where dozens of cell types coexist in close proximity.
Applications in Cancer Research
ATAC-seq has become a central tool in cancer epigenetics. A large-scale study published in Nature that profiled chromatin accessibility across 11 tumor types illustrates what the technique can uncover. Researchers identified specific regulatory regions that gain or lose accessibility as normal cells transform into cancer cells, and again as primary tumors progress to metastatic disease.
Some of these changes were shared across cancers. Regulatory regions near genes involved in drug resistance (like ABCC1) and blood vessel growth (VEGFA) became more accessible in multiple tumor types. Signaling pathways tied to the tumor suppressor TP53, low-oxygen response, and inflammation were linked to cancer initiation, while pathways involved in cell migration and tissue remodeling were tied to metastasis.
Other changes were cancer-specific. In triple-negative breast cancer, a developmental gene called EN1 gained dramatically increased chromatin accessibility compared to normal cells, pointing to epigenetic rewiring that drives tumor survival. In pancreatic cancer, accessibility changes around the genes KLF6 and PPARG highlighted regulatory elements tied to worse patient outcomes. The study also identified potential drug targets: chromatin accessibility around EGFR in kidney cancer and FGFR2 in brain tumors and breast cancer suggested these genes might be therapeutically targetable in those specific contexts.
These findings illustrate what makes ATAC-seq uniquely valuable in cancer biology. It captures the regulatory layer of information that sits between genetic mutations and actual gene expression, revealing how cells reprogram themselves during disease progression even when the DNA sequence itself hasn’t changed.
How It Compares to Related Techniques
ATAC-seq occupies a specific niche among genomic methods. RNA-seq tells you which genes are actively being expressed, but not why. ChIP-seq tells you where a specific protein binds DNA, but requires a separate experiment for each protein and much more starting material. ATAC-seq tells you which regulatory regions are physically open and available, providing the upstream context that explains gene expression patterns.
Compared to DNase-seq, which also maps open chromatin, ATAC-seq requires far fewer cells (as few as 1,000 to 50,000 versus the much larger quantities DNase-seq historically needed) and involves fewer experimental steps. The tagmentation reaction is also an endpoint reaction, meaning it naturally stops rather than continuing to digest the chromatin, which reduces the risk of artifacts from over-processing. These practical advantages are the main reason ATAC-seq has largely replaced DNase-seq as the default method for chromatin accessibility profiling.